Stelis Biopharma and Oncobiologics announced that they will unveil a new contract development and manufacturing effort. Marketed under the name, Bio2Source, Oncobiologics and Stelis Biopharma will offer development stage biotech companies access to a suite of CDMO services.
Oncobiologics will utilize its proprietary BioSymphony platform to offer mammalian cell process development and bulk drug manufacturing, while Stelis will offer microbial development and manufacturing capabilities as well as fill-finish services, including drug formulation development and lyophilization for biological products.
The Bio2Source initiative is facilitated by GMS Tenshi, a significant strategic investor both in Stelis Biopharma and Oncobiologics. GMS Tenshi, based in Singapore is a joint-venture between Tenshi Life Sciences Private Limited, an India based life sciences company and GMS Holdings, a Jordan based group with diversified assets across the pharmaceutical and biopharmaceutical space.
Oncobiologics is a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex monoclonal antibody (mAb) therapeutics. Oncobiologics is advancing a pipeline of innovative and biosimilar product candidates, three of which are currently in, or about to enter, clinical development.
Stelis Biopharma, headquartered in Bengaluru, India, is a vertically integrated biopharmaceutical company with R&D, process scale-up and end-to-end manufacturing capabilities from biological drug substance to aseptic fill-finish in various injectable formats.